Monthly ICOPE monitoring for older adults with multiple myeloma
Official title: Onco-ICOPE: ICOPE Program Feasibility in the Management of Myeloma Patients Over 70 Years
Run by University Hospital, Toulouse · NCT06247189 · Data updated 2026-11-12
We will test whether monthly ICOPE monitoring can catch early signs of functional decline and help maintain independence in people over 70 with multiple myeloma.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 70 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Status | Recruiting |
| Started | December 3, 2025 |
| Main results expected | December 3, 2026 |
| Study ends | December 30, 2026 |
| Registry record updated | December 22, 2025 |
| Trial ID | NCT06247189 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged over 70 with multiple myeloma starting first- or second-line treatment who can read and speak French and use a smartphone, tablet, or computer (or have a caregiver who can).
✕Probably not a fit
Patients in palliative care, those under legal guardianship, unable to use digital tools or understand the program, or with very limited life expectancy are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center feasibility project adapts the WHO ICOPE MONITOR program to a monthly rhythm for elderly patients with multiple myeloma to detect earlier declines in intrinsic capacity across mobility, memory, nutrition, mood, vision, and hearing. At inclusion patients undergo step 1 assessments of functional autonomy, quality of life, a clinical exam, and hematologic data collection, then enter monthly digital monitoring via an app or chatbot. When abnormalities are detected, the protocol triggers further geriatric steps and individualized care plans to try to limit decline. The program targets patients able to use digital tools and is conducted at CHU de Toulouse.
Why it matters
Potential benefit: If successful, this approach could detect problems earlier and enable timely, personalized interventions that help preserve independence and reduce treatment interruptions.
How similar studies have gone: The ICOPE framework has shown promise for monitoring older adults in other settings, but a monthly adaptation specifically for older myeloma patients is a novel approach without established results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female aged over 70 years, * Patient with multiple myeloma * WHO performance status 0-3, * Patient eligible for first- or second-line treatment * Patient willing to participate in ICOPE MONITOR program * Patient or caregiver able to use digital tools of ICOPE MONITOR: application or chatbot (computer or tablet or smartphone) * Patient with a life expectancy of more than 3 months, * Patient or caregiver able to understand, read and speak French * Person affiliated or benefiting from a social security. * Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research) Exclusion Criteria: * Patient in palliative care * Patient participating in a study evaluating another frailty prevention program * Patient unable to understand the study * Patient under court protection, guardianship or curatorship, * Patient refusal.
Where it's running
-
CHU de Toulouse
Toulouse, France Recruiting
Study contacts
- Principal investigator: Gilles BOURGADE — University Hospital, Toulouse
- Study coordinator: Gilles BOURGADE
- Email: bourgade.g@chu-toulouse.fr
- Phone: 06 04 54 59 39
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dynamic frailty-tailored therapy for elderly patients with newly diagnosed multiple myeloma
This study is testing a new treatment plan for older patients with newly diagnosed multiple myeloma to see if adjusting their therapy based on their fitness level helps them tolerate the treatment better and have improved outcomes.
-
Postprandial drop and frailty in older adults having planned noncardiac surgery
This study tests whether a drop in blood pressure after meals and frailty predict low blood pressure after anesthesia starts in adults 65 and older undergoing planned noncardiac surgery.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma
In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.
-
Frailty Training for Emergency Nurses in Morocco
This trial tests whether a four-module training program helps Moroccan emergency nurses recognize and care for frail older adults in the ER.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.